Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 8/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714889 | 0.90 | MAPK10 (0.53) | MAPK10MAPK14MAPK9ALDH1A1TDP1 | |
| SCHEMBL6718578 | 0.86 | MAPK10 (0.43) | MAPK10MAPK14MAPK9ALDH1A1TDP1 | |
| SCHEMBL6779933 | 0.85 | MAPK10 (0.48) | MAPK10MAPK14MAPK9LMNASMN1; SMN2 | |
| SCHEMBL6717995 | 0.85 | SMN1; SMN2 (0.49) | ALDH1A1LMNASMN1; SMN2TDP2 | |
| SCHEMBL28340992 | 0.79 | MAPK10 (0.58) | MAPK10MAPK14MAPK9ALDH1A1LMNA | |
| SCHEMBL6718815 | 0.78 | MAPK10 (0.51) | MAPK10MAPK14MAPK9LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6718286 | 0.77 | MAPK10 (0.53) | MAPK10MAPK14MAPK9ALDH1A1LMNA | |
| SCHEMBL6715013 | 0.76 | MAPK10 (0.53) | MAPK10MAPK14MAPK9ALDH1A1LMNA | |
| SCHEMBL27601351 | 0.76 | MAPK10 (0.52) | MAPK10MAPK14MAPK9ALDH1A1CNR1 | |
| Hydrochloric Acid SCHEMBL6715145 | 0.75 | CA1 (0.48) | MAPK10MAPK14MAPK9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818651-B2 | ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1337515-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002040450-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | PDE7B, PDE3B, PDE3A | MAPK10 1836/4885MAPK14 2713/4885MAPK9 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.